dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Ruiz Rodriguez, Juan Carlos |
dc.contributor.author | Molnar, Zsolt |
dc.contributor.author | Deliargyris, Efthymios N. |
dc.contributor.author | Ferrer Roca, Ricard |
dc.date.accessioned | 2022-04-07T12:39:10Z |
dc.date.available | 2022-04-07T12:39:10Z |
dc.date.issued | 2021 |
dc.identifier.citation | Ruiz-Rodríguez JC, Molnar Z, Deliargyris EN, Ferrer R. The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences. Crit Care Res Pract. 2021;2021:7769516. |
dc.identifier.issn | 2090-1313 |
dc.identifier.uri | https://hdl.handle.net/11351/7329 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; CytoSorb; Therapy |
dc.description.abstract | The COVID-19 pandemic has led to the biggest global health crisis of our lifetime. There is accumulating evidence that a substantial number of critically ill COVID-19 patients exhibit a dysregulated host response manifesting as cytokine storm or cytokine release syndrome, which in turn contributes to the high observed rates of mortality. Just as in other hyperinflammatory conditions, extracorporeal cytokine removal may have potential beneficial effects in this subgroup of COVID-19 patients. The CytoSorb blood purification device is the most extensively investigated cytokine removal platform with considerable evidence suggesting that early intervention can provide rapid hemodynamic stabilization and improvement in vital organ functions. The purpose of this review is to provide an overview of the pathophysiological background of hyperinflammation in COVID-19 and to summarize the currently available evidence on the effects of hemoadsorption in these patients. |
dc.language.iso | eng |
dc.publisher | Hindawi |
dc.relation.ispartofseries | Critical Care Research and Practice;2021 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | COVID-19 (Malaltia) - Mortalitat |
dc.subject | Citocines - Purificació |
dc.subject | Proteïnes de la sang |
dc.subject.mesh | Hemadsorption |
dc.subject.mesh | Cytokines |
dc.subject.mesh | /adverse effects |
dc.subject.mesh | Coronavirus Infections |
dc.title | The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1155/2021/7769516 |
dc.subject.decs | hemadsorción |
dc.subject.decs | citocinas |
dc.subject.decs | /efectos adversos |
dc.subject.decs | infecciones por Coronavirus |
dc.relation.publishversion | https://doi.org/10.1155/2021/7769516 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Ruiz-Rodríguez JC, Ferrer R] Servei de Cures Intensives, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Disfunció d'Òrgans de Xoc i Reanimació, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Molnar Z] CytoSorbents Europe GmbH, Berlin, Germany. Institute for Translational Medicine, School of Medicine, University of Pécs, Pécs, Hungary. Department of Anesthesiology and Intensive Therapy, Poznan University of Medical Sciences, Poznan, Poland. Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary. [Deliargyris EN] CytoSorbents Corporation, Monmouth Junction, NJ, USA |
dc.identifier.pmid | 34336280 |
dc.identifier.wos | 000683119800002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |